Table 1.
Outcomes and follow-up periods
| Studies | Outcomes reported | Follow-up periods | DDC versus control group |
|---|---|---|---|
| CURRENT OASIS 7 [11] | CV death, MI, or stroke (MACE); CV death, MI, stroke, total mortality, TIMI major bleeding, minor bleeding, fatal bleeding, intracranial bleeding | 30 days | DDC versus SDAPT |
| ACCEL AMI [12] | Minor bleeding | 30 days | DDC versus SDAPT |
| OPTIMUS2007 [13] | Bleeding complications | 30 days | DDC versus SDAPT |
| CREATIVE [14] | MACE, all-cause death, cardiac death, MI, TVR, stroke, ST, major bleeding | 18 months | DDC versus SDAPT |
| Chen2017 [15] | MACE, in-stent thrombosis, TVR, MI, cardiac death, bleeding events, mild bleeding, severe bleeding | 12 months | DDC versus SDAPT |
| Khatri2013 [16] | Composite efficacy outcomes, any bleeding event | 23 months | DDC versus prasugrel |
| OPTIMUS3 [17] | Major and minor TIMI defined bleeding, adverse drug events | 7 days | DDC versus prasugrel |
| PRINCIPLE TIMI 44 [18] | TIMI major and minor bleeding, minor bleeding, hemorrhagic adverse events, MI | 2 weeks | DDC versus prasugrel |
| Tailor2014 [19] | MACE, MI, ST, CV death, stroke | 1 month and 571 days | DDC versus prasugrel |
| Chen2017 [15] | MACE, in-stent thrombosis, TVR, MI, cardiac death, bleeding events, mild bleeding, severe bleeding | 12 months | DDC versus ticagrelor |
| Wu2017 [20] | MACE, minimal bleeding, minor bleeding | 30 days | DDC versus ticagrelor |
| ACCEL AMI [12] | Minor bleeding | 30 days | DDC versus TAPT |
| ACCEL DM [21] | Bleeding event | 30 days | DDC versus TAPT |
| CREATIVE [14] | MACE, all-cause death, cardiac death, MI, TVR, stroke, ST, major bleeding | 18 months | DDC versus TAPT |
| Ha2013 [22] | MACE | 1 month | DDC versus TAPT |
| HOST ASSURE [23] | MACE, cardiac death, MI, stroke, ST, all-cause death, TLR, TVR, PLATO minor bleeding | 30 days | DDC versus TAPT |
| Jeong2009 [24] | MACE, major and minor bleeding | 30 days | DDC versus TAPT |
Abbreviations: TAPT: triple antiplatelet therapy consisting of aspirin, clopidogrel and cilostazol, DDC: double dose clopidogrel, SDAPT: standard dual antiplatelet therapy, CV: cardiovascular, MI: myocardial infarction, ST: stent thrombosis, MACE: major adverse cardiac events, TIMI: thrombolysis in myocardial infarction, TVR: target vessel revascularization, TLR: target lesion revascularization